Molecular Partners $64 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Charles River Laboratories acquisition of Vigene Biosciences
We are advising Charles River on the acquisition
Vaccitech $110.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Aveanna $458.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Privia Health $525.8 million IPO
We advised Privia Health on its IPO and Nasdaq listing
Roivant Sciences combination with Montes Archimedes Acquisition
We are advising Roivant Sciences on its combination with a SPAC
NeuroPace $102 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Akoya Biosciences $151.3 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing